Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RGEN's Cash to Debt is ranked higher than
99% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. RGEN: No Debt )
RGEN' s 10-Year Cash to Debt Range
Min: 143.42   Max: No Debt
Current: No Debt

Equity to Asset 0.87
RGEN's Equity to Asset is ranked higher than
89% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. RGEN: 0.87 )
RGEN' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.97
Current: 0.87

0.52
0.97
Interest Coverage 213.82
RGEN's Interest Coverage is ranked higher than
54% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RGEN: 213.82 )
RGEN' s 10-Year Interest Coverage Range
Min: 194.44   Max: 9999.99
Current: 213.82

194.44
9999.99
F-Score: 4
Z-Score: 39.24
M-Score: -2.05
WACC vs ROIC
10.14%
15.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.82
RGEN's Operating margin (%) is ranked higher than
93% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. RGEN: 16.82 )
RGEN' s 10-Year Operating margin (%) Range
Min: -312.44   Max: 186.01
Current: 16.82

-312.44
186.01
Net-margin (%) 12.85
RGEN's Net-margin (%) is ranked higher than
90% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. RGEN: 12.85 )
RGEN' s 10-Year Net-margin (%) Range
Min: -224.93   Max: 192.3
Current: 12.85

-224.93
192.3
ROE (%) 7.36
RGEN's ROE (%) is ranked higher than
91% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. RGEN: 7.36 )
RGEN' s 10-Year ROE (%) Range
Min: -47.55   Max: 82.79
Current: 7.36

-47.55
82.79
ROA (%) 6.54
RGEN's ROA (%) is ranked higher than
92% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. RGEN: 6.54 )
RGEN' s 10-Year ROA (%) Range
Min: -43.4   Max: 75.79
Current: 6.54

-43.4
75.79
ROC (Joel Greenblatt) (%) 41.95
RGEN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. RGEN: 41.95 )
RGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -779.69   Max: 1086.81
Current: 41.95

-779.69
1086.81
Revenue Growth (3Y)(%) 29.00
RGEN's Revenue Growth (3Y)(%) is ranked higher than
92% of the 782 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. RGEN: 29.00 )
RGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -43.2   Max: 45.6
Current: 29

-43.2
45.6
EBITDA Growth (3Y)(%) 109.50
RGEN's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. RGEN: 109.50 )
RGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.7   Max: 109.5
Current: 109.5

-65.7
109.5
» RGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RGEN Guru Trades in Q1 2014

Paul Tudor Jones 24,627 sh (New)
Joel Greenblatt 15,504 sh (-16.34%)
Jim Simons 465,993 sh (-17.29%)
» More
Q2 2014

RGEN Guru Trades in Q2 2014

Jim Simons 707,200 sh (+51.76%)
Paul Tudor Jones Sold Out
Joel Greenblatt 14,914 sh (-3.81%)
» More
Q3 2014

RGEN Guru Trades in Q3 2014

Jim Simons 855,504 sh (+20.97%)
Joel Greenblatt 12,871 sh (-13.70%)
» More
Q4 2014

RGEN Guru Trades in Q4 2014

Joel Greenblatt 13,954 sh (+8.41%)
Jim Simons 694,304 sh (-18.84%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 127.40
RGEN's P/E(ttm) is ranked higher than
87% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 127.40 )
RGEN' s 10-Year P/E(ttm) Range
Min: 3.19   Max: 762.86
Current: 127.4

3.19
762.86
Forward P/E 37.45
RGEN's Forward P/E is ranked higher than
86% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 37.45 )
N/A
PE(NRI) 130.30
RGEN's PE(NRI) is ranked higher than
90% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 130.30 )
RGEN' s 10-Year PE(NRI) Range
Min: 3.19   Max: 534
Current: 130.3

3.19
534
P/B 9.30
RGEN's P/B is ranked higher than
53% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. RGEN: 9.30 )
RGEN' s 10-Year P/B Range
Min: 1.42   Max: 10.19
Current: 9.3

1.42
10.19
P/S 16.48
RGEN's P/S is ranked higher than
65% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. RGEN: 16.48 )
RGEN' s 10-Year P/S Range
Min: 2.74   Max: 18.1
Current: 16.48

2.74
18.1
PFCF 80.60
RGEN's PFCF is ranked higher than
90% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 80.60 )
RGEN' s 10-Year PFCF Range
Min: 3.18   Max: 379
Current: 80.6

3.18
379
POCF 59.22
RGEN's POCF is ranked higher than
91% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 59.22 )
RGEN' s 10-Year POCF Range
Min: 3.15   Max: 99999999.99
Current: 59.22

3.15
99999999.99
EV-to-EBIT 94.39
RGEN's EV-to-EBIT is ranked higher than
90% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 94.39 )
RGEN' s 10-Year EV-to-EBIT Range
Min: -2288.9   Max: 2812.1
Current: 94.39

-2288.9
2812.1
Shiller P/E 201.50
RGEN's Shiller P/E is ranked higher than
93% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 201.50 )
RGEN' s 10-Year Shiller P/E Range
Min: 11.63   Max: 217.19
Current: 201.5

11.63
217.19
Current Ratio 7.58
RGEN's Current Ratio is ranked higher than
83% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. RGEN: 7.58 )
RGEN' s 10-Year Current Ratio Range
Min: 1.95   Max: 29.8
Current: 7.58

1.95
29.8
Quick Ratio 6.42
RGEN's Quick Ratio is ranked higher than
81% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. RGEN: 6.42 )
RGEN' s 10-Year Quick Ratio Range
Min: 1.8   Max: 29.34
Current: 6.42

1.8
29.34
Days Inventory 160.97
RGEN's Days Inventory is ranked higher than
85% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 160.97 )
RGEN' s 10-Year Days Inventory Range
Min: 70.97   Max: 730
Current: 160.97

70.97
730
Days Sales Outstanding 44.57
RGEN's Days Sales Outstanding is ranked higher than
89% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. RGEN: 44.57 )
RGEN' s 10-Year Days Sales Outstanding Range
Min: 6.73   Max: 126.28
Current: 44.57

6.73
126.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.60
RGEN's Price/Net Cash is ranked higher than
64% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 86.70 vs. RGEN: 24.60 )
RGEN' s 10-Year Price/Net Cash Range
Min: 2.6   Max: 25.53
Current: 24.6

2.6
25.53
Price/Net Current Asset Value 19.20
RGEN's Price/Net Current Asset Value is ranked higher than
64% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 39.00 vs. RGEN: 19.20 )
RGEN' s 10-Year Price/Net Current Asset Value Range
Min: 2.28   Max: 18.02
Current: 19.2

2.28
18.02
Price/Tangible Book 12.40
RGEN's Price/Tangible Book is ranked higher than
56% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. RGEN: 12.40 )
RGEN' s 10-Year Price/Tangible Book Range
Min: 1.22   Max: 14.59
Current: 12.4

1.22
14.59
Price/DCF (Projected) 5.20
RGEN's Price/DCF (Projected) is ranked higher than
93% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 5.20 )
RGEN' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 3.25
Current: 5.2

0.8
3.25
Price/Median PS Value 2.60
RGEN's Price/Median PS Value is ranked higher than
69% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. RGEN: 2.60 )
RGEN' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 11.06
Current: 2.6

0.24
11.06
Price/Graham Number 8.40
RGEN's Price/Graham Number is ranked higher than
89% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RGEN: 8.40 )
RGEN' s 10-Year Price/Graham Number Range
Min: 0.65   Max: 5.61
Current: 8.4

0.65
5.61
Earnings Yield (Greenblatt) 1.00
RGEN's Earnings Yield (Greenblatt) is ranked higher than
86% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. RGEN: 1.00 )
RGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 57.8
Current: 1

0.1
57.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RGN.Germany,
Repligen Corp was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies. It is also engaged in the manufacture of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of biomanufacturing technologies, it has developed and currently markets a series of OPUS or Open-Platform, User-Specified chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures seven forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. On December 28, 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. On January 21, 2014, it also out-licensed its histone deacetylase inhibitor portfolio which includes the Friedreich's ataxia program, to BioMarin Pharmaceuticals Inc., or BioMarin. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. It sells its bioprocessing products through direct sales force to partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and to distributors in certain foreign markets.
» More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Reports First Quarter Fiscal Year 2010 Financial Results Aug 06 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
Biotech execs remember MIT professor: ‘He inspired so many scientists’ May 01 2015
Nasdaq stocks posting largest percentage increases Apr 29 2015
Repligen to Report First Quarter 2015 Financial Results Apr 29 2015
Repligen to Report First Quarter 2015 Financial Results Apr 29 2015
REPLIGEN CORP Financials Mar 24 2015
Repligen (RGEN) Enters Overbought Territory - Tale of the Tape Mar 20 2015
REPLIGEN CORP Files SEC form 10-K, Annual Report Mar 17 2015
Repligen reports 4Q loss Mar 13 2015
Repligen reports 4Q loss Mar 13 2015
REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 13 2015
Repligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance Mar 13 2015
Q4 2014 Repligen Corp Earnings Release - Before Market Open Mar 13 2015
Repligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance Mar 13 2015
Repligen to Report Year 2014 Financial Results and Provide 2015 Financial Guidance Mar 09 2015
Repligen to Report Year 2014 Financial Results and Provide 2015 Financial Guidance Mar 09 2015
REPLIGEN CORP Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements... Mar 02 2015
Repligen Completes Expansion of U.S. Facility Feb 10 2015
Repligen to Present at 2015 Leerink Global Healthcare Conference Feb 04 2015
REPLIGEN CORP Files SEC form 8-K, Termination of a Material Definitive Agreement Jan 30 2015
Repligen (RGEN) Shares March Higher, Can It Continue? - Tale of the Tape Jan 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK